Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 9 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Genmab A/S has 18 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 16 distinct examiners and 9 distinct art units, indicating substantial dispersion across examination personnel and technical groupings. That structure makes centralized docket oversight important, because prosecution positions may develop along several independent paths.
SKELDING, ZACHARY S is the busiest examiner, with 3 pending matters. The assignment is a focal point within the portfolio, but the broader examiner distribution means it should not be treated as representative of every pending case. Counsel should monitor examiner-specific treatment of claim construction, biological evidence, and cited art.
The art-unit spread also supports systematic issue tracking. A coordinated review can identify recurring disclosure and patentability themes, while keeping amendments tied to the record of each application. Consistency in terminology and technical explanations may help manage the portfolio, but each response still requires attention to its assigned examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (12%) |
| §112 only | 4 (24%) |
| Double-patenting only | 2 (12%) |
| Double-patenting + other | 4 (24%) |
| Multi-statute (no §101) | 2 (12%) |
| No statute on record | 3 (18%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 2 | 59.8% | +41.1% |
| EMCH, GREGORY S | 1 | 48.0% | +43.2% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
| SULLIVAN, DENNIS JOHN | 1 | 57.6% | +48.0% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18109708 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | — |
| 17046199 | AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT | ROONEY, NORA MAUREEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025202 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | PETERS, ALEC JON | 19d |
| 18579086 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN COMBINATION THERAPY FOR CANCER | EMCH, GREGORY S | — |
| 18526959 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR | SZPERKA, MICHAEL EDWARD | — |
| 18507869 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF | DAHLE, CHUN WU | — |
| 18500799 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | XIAO, YAN | — |
| 18556240 | ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME | SULLIVAN, DENNIS JOHN | — |
| 18281372 | NON-ACTIVATING ANTIBODY VARIANTS | METCALF, MATTHEW CURRAN | — |
| 18025203 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1641 | 4 |
| 1642 | 4 |
| 1644 | 3 |
| 1678 | 1 |
| 1647 | 1 |
| 1643 | 1 |
| 1672 | 1 |
| 1674 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18579086 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN COMBINATION THERAPY FOR CANCER | EMCH, GREGORY S | 1678 | §103Other | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18526959 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR | SZPERKA, MICHAEL EDWARD | 1641 | §112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18507869 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF | DAHLE, CHUN WU | 1641 | §112Other | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18500799 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | XIAO, YAN | 1642 | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18556240 | ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME | SULLIVAN, DENNIS JOHN | 1642 | §112DP | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18281372 | NON-ACTIVATING ANTIBODY VARIANTS | METCALF, MATTHEW CURRAN | 1647 | Other | Final Rejection | — | Pending | Sep 11, 2023 |
| 18025203 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Mar 08, 2023 |
| 18025202 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | PETERS, ALEC JON | 1641 | DP | Final Rejection | 19d | Pending | Mar 08, 2023 |
| 18023808 | ANTIBODY THERAPY | SALVOZA, M FRANCO G | 1672 | §103§112DP | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18109708 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | 1644 | §102§112Other | Non-Final OA | — | Pending | Feb 14, 2023 |
| 18160386 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | MOSELEY II, NELSON B | 1642 | §103 | Final Rejection | — | Pending | Jan 27, 2023 |
| 18010783 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | BELYAVSKYI, MICHAIL A | 1644 | §103DP | Final Rejection | 7d | Pending | Dec 15, 2022 |
| 17972867 | MONOCLONAL ANTIBODIES AGAINST C-MET | KAUFMAN, CLAIRE M | 1674 | §112Other | Non-Final OA | 18d overdue | Pending | Oct 25, 2022 |
| 17714735 | MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH IMPROVED INTERNALIZATION CHARACTERISTICS | GODDARD, LAURA B | 1642 | §112 | Non-Final OA | — | Pending | Apr 06, 2022 |
| 17046199 | AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT | ROONEY, NORA MAUREEN | 1641 | §102§103Other | Non-Final OA | — | Pending | Oct 08, 2020 |
| 16891796 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | PUTTLITZ, KARL J | 1646 | Other | Final Rejection | — | Pending | Jun 03, 2020 |
| 16582428 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | 1644 | Other | Non-Final OA | — | Pending | Sep 25, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenmab A/S has 17 pending office actions as of October 2026, spread across 9 art units and 16 examiners.
Zachary S Skelding has the most, with 2 of Genmab A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
